Abstract

In 2003, Eli Lilly and Company faced a threat to its philanthropic reputation on several fronts. Consumers were concerned about escalating drug prices, and the pharmaceutical industry was criticized for being slow to provide HIV/AIDS drugs in developing countries. Eli Lilly Chief Executive Sidney Taurel sought to develop a corporate social responsibility strategy that would set his company apart from the industry. Options included expanding the company's diabetes program or broadening support for treatment of multi-drug-resistant tuberculosis. In this case students study the pharmaceutical industry's sales, R&D and philanthropic giving, as well as regional demographics and their leading causes of death, to create a recommendation for revitalizing Eli Lilly's social responsibility strategy.

Citation

Kogut, Bruce, and Jerry Kim. Eli Lilly: A Strategy for Developing Companies. Columbia University: The Jerome Chazen Case Series, Fall 2009.

Each author name for a Columbia Business School faculty member is linked to a faculty research page, which lists additional publications by that faculty member.

Each topic is linked to an index of publications on that topic.